Sotagliflozin (Inpefa) Label Expansion 2026: What Dual SGLT1/SGLT2 Inhibition Means for HFpEF Patients With Diabetes
Quick Facts
Why Is the HFpEF Indication Significant for Patients With Type 2 Diabetes?
For decades, HFpEF was sometimes called the 'unsolved problem' in cardiology. Unlike heart failure with reduced ejection fraction (HFrEF), where multiple drug classes have proven survival benefits, HFpEF resisted pharmacological intervention in major trials. Patients with coexisting type 2 diabetes carry an even higher burden: population studies have shown that diabetic HFpEF patients have roughly 30–40% higher rates of hospitalization compared to non-diabetic HFpEF patients, according to data published in the European Heart Journal in 2019.
The expanded sotagliflozin indication is clinically meaningful because it offers a single oral tablet that targets both the cardiac and metabolic dimensions of disease. The SOLOIST-WHF investigators reported that the treatment effect was consistent regardless of baseline ejection fraction, with pre-specified subgroup analyses showing benefit in patients with EF above 50%. This finding, combined with the favorable safety profile observed across both pivotal trials, supported the FDA's decision to broaden the label. For clinicians managing the overlap of diabetes and HFpEF, the approval simplifies treatment by reducing the need to prescribe separate agents for glucose control and cardiac protection.
How Does Intestinal SGLT1 Blockade Provide Benefits Beyond Kidney-Based SGLT2 Inhibition?
SGLT1 transporters in the brush border of the small intestine are responsible for absorbing the majority of ingested glucose. When sotagliflozin inhibits these transporters, glucose absorption is delayed and partially shifted to more distal segments of the gut. Research published in Diabetes Care has demonstrated that this redistribution stimulates the release of glucagon-like peptide-1 (GLP-1) and peptide YY from intestinal L-cells, hormones that improve insulin secretion, suppress appetite, and slow gastric emptying.
This intestinal mechanism produces measurably different pharmacodynamic effects compared to selective SGLT2 inhibitors. In the SCORED trial, sotagliflozin reduced HbA1c by approximately 0.56% at 12 months in patients with type 2 diabetes and chronic kidney disease, even in those with estimated GFR between 25 and 45 mL/min/1.73 m² — a population where renal SGLT2 inhibition loses much of its glucose-lowering potency due to reduced glomerular filtration. The preserved glycemic efficacy in advanced CKD is attributed to the gut-based SGLT1 component, which functions independently of kidney function. This pharmacological distinction may prove especially valuable in the substantial proportion of HFpEF patients who also have impaired renal function.
What Practical Considerations Should Patients and Clinicians Know About Inpefa Prescribing?
The recommended dosing for sotagliflozin is 200 mg once daily taken before the first meal, with the option to increase to 400 mg based on tolerability. The timing relative to meals is important because SGLT1 inhibition in the gut is most effective when the drug is present before dietary glucose arrives in the small intestine. In the SOLOIST-WHF trial, the median time to clinical benefit was observed within days of treatment initiation, with event curves separating early in the study period.
The gastrointestinal side effect profile differs from selective SGLT2 inhibitors. Diarrhea occurred in approximately 8–10% of sotagliflozin-treated patients versus 4–5% in placebo groups in the pivotal trials, attributable to unabsorbed glucose reaching the colon where it undergoes bacterial fermentation. This effect is generally self-limiting, resolving within two to four weeks as the gut microbiome adapts. Standard SGLT2 inhibitor class precautions apply, including monitoring for euglycemic diabetic ketoacidosis, particularly in patients using insulin or those with reduced caloric intake. The prescribing information also advises volume status assessment before initiation, consistent with the class effect of osmotic diuresis through renal glucosuria.
Frequently Asked Questions
The original May 2023 approval covered heart failure broadly in adults, but the expanded HFpEF indication specifically applies to patients with type 2 diabetes, reflecting the population studied in the pivotal trials. Clinicians should consult the current prescribing information for the full scope of approved indications.
In the SOLOIST-WHF trial, the treatment benefit emerged rapidly, with separation in event curves observed within the first few weeks. This early benefit is consistent with hemodynamic effects such as natriuresis and volume reduction. However, individual responses vary, and patients should continue therapy as directed even if they do not notice immediate symptom improvement.
Yes, the SGLT1 inhibition component causes mild diarrhea more frequently than selective SGLT2 inhibitors, affecting roughly 8–10% of patients in clinical trials. This occurs because blocking intestinal glucose absorption allows unabsorbed sugars to reach the large intestine. The symptom typically improves within the first few weeks of treatment and can be minimized by starting at the lower 200 mg dose.
References
- Bhatt DL et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-128.
- Bhatt DL et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129-139.
- U.S. Food and Drug Administration. FDA Approves Treatment for Heart Failure in Adults. FDA News Release, May 26, 2023.
- Packer M et al. Heart Failure With a Preserved Ejection Fraction and Diabetes Mellitus. European Heart Journal. 2019;40(39):3267-3276.
- Powell DR et al. Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption. J Clin Endocrinol Metab. 2020;105(4):e1235-e1249.